

1 The mutational steps of SARS-CoV-2 to become like Omicron within seven 2 months: the story of immune escape in an immunocompromised patient

3
4 Sissy Therese Sonnleitner^{1,2*}, Martina Prelog^{3*}, Stefanie Sonnleitner¹, Eva Hinterbichler¹,
5 Hannah Halbfurter¹, Dominik B. C. Kopecky¹, Giovanni Almanzar³, Stephan Koblmüller⁴,
6 Christian Sturmbauer⁴, Leonard Feist⁵, Ralf Horres⁵, Wilfried Posch², Gernot Walder¹.

7 ¹ Dr. Gernot Walder GmbH, Medical Laboratory, Department of Virology, 9931 Ausservillgraten 30,
8 Austria.

9 ² Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck,
10 Austria.

11 ³ Pediatric Rheumatology/Special Immunology, Department of Pediatrics, University Hospital
12 Wuerzburg, Josef-Schneider-Str. 2, Wuerzburg, Germany.

13 ⁴ Institute of Biology, University of Graz, Universitätsplatz 2, 8010 Graz, Austria.

14 ⁵ GenXPro GmbH, Altenhoeferallee 3, 60438 Frankfurt am Main, Germany

15
16 *These authors contributed equally.

17
18 Corresponding author: sissy.sonnleitner@infektiologie.tirol
19

20 ABSTRACT

21 We studied a unique case of prolonged viral shedding in an immunocompromised patient
22 that generated a series of SARS-CoV-2 immune escape mutations over a period of seven
23 months. During the persisting SARS-CoV-2 infection seventeen non-synonymous mutations
24 were observed, thirteen (13/17; 76.5%) of which occurred in the genomic region coding for
25 spike. Fifteen (15/17; 88.2%) of these mutations have already been described in the context
26 of variants of concern and include the prominent immune escape mutations S:E484K,
27 S:D950N, S:P681H, S:N501Y, S:del(9), N:S235F and S:H655Y. Fifty percent of all mutations
28 acquired by the investigated strain (11/22) are found in similar form in the Omicron variant of
29 concern. The study shows the chronology of the evolution of intra-host mutations, which can
30 be seen as the straight mutational response of the virus to specific antibodies and should
31 therefore be given special attention in the rating of immune escape mutations of SARS-CoV-
32 2.

34 INTRODUCTION

35 In December 2019 the Wuhan Municipal Health Commission (China) reported a cluster of
36 cases of pneumonia of unknown etiology to the WHO China Country Office. By the beginning
37 of 2020 it was confirmed that a novel coronavirus later named severe acute respiratory
38 syndrome coronavirus (SARS-CoV-2), was the causative agent (1). SARS-CoV-2 spreads
39 easily and effectively among human beings with a basic reproduction number (R0) of > 2 (2,
40 3). Following this rapid human-to-human transmission and intercontinental spread the WHO
41 declared a global pandemic in March of 2020. The first cases in Austria were reported in
42 Ischgl, Tyrol, as early as February 2020 – and East Tyrol was considered one of the first
43 hotspot areas in Central Europe.

44 While mutations are common in RNA viruses and mostly will not make a significant
45 difference, some mutations proved to provide SARS-CoV-2 with a selective advantage, such
46 as increased transmissibility or increased escape from specific antibodies (4-8). Those

47 variants with proven or suspected immune escape mutations were deemed variants of
48 concern (VOC) or variants of interest (VOI), respectively, and require close monitoring
49 (<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>). The spread of the first
50 described variant of concern (Alpha variant, B.1.1.7, VOC) was confirmed early in Austria
51 and increased from 0.7% in January to > 99% in April 2021 in the study area East Tyrol
52 ([https://www.ages.at/themen/krankheitserreger/coronavirus/sars-cov-2-varianten-in-](https://www.ages.at/themen/krankheitserreger/coronavirus/sars-cov-2-varianten-in-oesterreich/)
53 [oesterreich/](https://www.ages.at/themen/krankheitserreger/coronavirus/sars-cov-2-varianten-in-oesterreich/)). As of December 2020, the European Center for Disease prevention and control
54 (ECDC) noticed a sharp decline of the Alpha variant in the European Union (EU; 14.5%)
55 followed by a fast spread of the Delta (B.1.617.2) in spring, 2021, plus a few shares of the
56 Gamma (P1 or B.1.1.28.1, 0.3%) and others virus variants (0.3%). By January 2022, these
57 variants have been largely replaced by the Omicron variant (B.1.1.529) in the study area.
58 The Omicron variant now accounts for > 95% of cases. Common in these successful variants
59 are a few specific genomic changes that give them a decisive benefit in terms of
60 transmission or replication, e.g. in the pharynx. The most prominent spike substitutions with
61 immune escape effect can be found in several VOC or VOI. For example, N501Y in the
62 Alpha, Beta and Omicron variant, a nucleotide exchange at position E484 to K in the Alpha-
63 (in a subvariant), Beta and Gamma, to Q in a Delta subvariant or to A in both Omicron
64 subvariants BA.1 and BA.2. Furthermore, P681H is found in the Alpha and Omicron variant
65 as well as in the VOI B.1.1.238 and the spike deletions 144/145 described as recurrent
66 deletion regions, since they multiply occurred (9, 10).

67 The origin of immune escape variants is still a matter of speculation. Several hypotheses
68 take zoonotic origin, selective pressure during treatment with antiviral drugs, monoclonal
69 antibodies or convalescent plasma into consideration and a few studies point to the
70 significance of the exceptional intra-host environment of immunocompromised patients to
71 explain the evolution of immune escape variants (11-13). Those cases showed especially
72 long-lasting viable viral shedding of SARS-CoV-2 in immunosuppressed patients for a period
73 of more than four months (11-13). Two of the patients treated with monoclonal and
74 convalescent plasma showed unusually high numbers of nucleotide changes and deletion
75 mutations (12, 13), among others the already described immune escape mutation S:del69/70
76 (13).

77 In November 2020 we became aware of a patient in her 60ies with lymphoma who showed
78 persistingly high pharyngeal viral loads of SARS-CoV-2. Although the patient had detectable
79 SARS-CoV-2 specific antibody responses, she was unable to clear the virus load. Therefore,
80 close monitoring was performed by rtPCR of naso-pharyngeal swabs. This unusual case
81 prompted us to perform a thorough sequential serological screening as well as investigation
82 of virus mutant development. Viral titre and mutant development of SARS-CoV-2 was
83 monitored by regular naso-pharyngeal swabs with subsequent rtPCR and Next-Generation
84 Sequencing (NGS), which enabled us to monitor the chronology of the evolution of immune
85 escape mutations. We discuss these findings in the light of potential new sources of intra-
86 host escape mutations and with respect to adaptations of the vaccination strategy.

87

88 **METHODSRESULTS**

89 **Clinical presentation of an immunocompromised individual persistently infected with**
90 **SARS-CoV-2**

91 In August 2015, the patient was diagnosed with stage IVa small cell lymphocytic lymphoma,
92 complicated by a temporary reactivation of Epstein-Barr virus (EBV) with reactive
93 splenomegaly and rapid nodal progression. From June 2016, she was given six cycles of
94 Rituximab and Bendamustine, which led to remission. In October 2019, the patient suffered a
95 relapse with washout and 90% bone marrow infiltration (B-CLL Binet B or RAI III),
96 accompanied by pronounced B symptoms and antibody deficiency. Beginning in May 2020,
97 another round of therapy with Rituximab and Bendamustine was administered. It was
98 completed in November 2020 after six cycles. The leukocytes counted 4200/ μ L in the lower
99 normal range, platelets 136,000/ μ L, the immunoglobulins were clearly reduced (IgG 249
100 mg/dL, IgA 3 mg/dL, IgM 12 mg/dL).

101 Four days after the last chemotherapy – mid November 2020 - the patient fell ill with fever,
102 cough, headache and pain, but neither loss of taste nor smell. SARS-CoV-2 was detected in
103 the throat swab by rtPCR. The patient was in quarantine for ten days; a final PCR control
104 was not carried out. Due to persistent fatigue, recurrent fever episodes and persistent cough
105 with little white expectorate, the patient was again admitted to the hospital in the middle of
106 January, 2021 and rtPCR was again positive for SARS-CoV-2. At the same time there was a
107 recurrence of EBV. The patient was enrolled for an inhalation therapy with N-chlorotaurine (3
108 times daily inhalation of 10ml of N-chlorotaurine for three minutes and 10 - 14 days) (Nagl et
109 al., 2018; Cegolon et al., 2020) and received 15g intravenous immunoglobuline (IVIg,
110 Intratect®, Biotest Pharma GmbH, Dreieich, Germany) on admission. Ten days later; no
111 specific therapy with antibodies against SARS-CoV-2 having been carried out - the blood
112 findings were unchanged (leukocytes 5500/ μ L, platelets 102,000/ μ L (decreased), IgG 301
113 mg/dL, IgA 3 mg/dL, IgM 25 mg/dL), but the leukocyte typing showed a decline by the B-CLL
114 of 70% and a reduction of CD4+ helper T cells. The chest x-ray was normal. The patient
115 suffered from impaired general condition, headache and sore throat and was not able to
116 clear SARS-CoV-2 infection. The patient again received the IVIg therapy (IVIg, Intratect®,
117 Biotest Pharma GmbH, Dreieich, Germany). No antiviral therapeutics were administered to
118 the patient at any time of the infection. An increase of leukocytes was developed (21,600/ μ L).

119 Since the onset of the symptoms and the first rtPCR positive swab the patient was committed
120 to home quarantine in accordance with Austrian law. When symptoms did not clear after a
121 month, home quarantine was slightly lightened, yet, testing with naso-pharyngeal swabs and
122 subsequent rtPCR was continued. Persistent viral shedding was determined on day 102, day
123 124, day 182 and day 205 since onset of symptoms and first positive rtPCR and the viral
124 shedding from the upper respiratory tract has continued to date (**Figure 1**). The patient gave
125 full written consent for the case to be attended and published.

126 **Isolation**

127 Isolation trials were performed from swab samples taken on day 73, 93, 99, 104, 109, 117,
128 127, 133 and 182 on VeroB4-cells and were successful on day 73, 93, 109 and 127. The
129 isolation success correlated negatively with the Ct-values of the swab ($k = -0.59$).

130

131

132

133 **Figure 1:** Timeline of the course of disease in an immunocompromised female patient with
134 almost continuous viral shedding throughout the study period of 207 days. Ct ...Cycle

135 threshold; IVIG therapy ... intravenous immunoglobuline therapy; RTX ... Rituximab and
136 Bendamustine therapy.

137

138 **Serology**

139 At the same time points, specific antibodies were investigated using three different
140 serological tools. An overview of the serological results is given in **Table 1**. On day 102 the
141 IgG titres in general and neutralizing antibody titres in particular, were observed in a low
142 degree with an IgG titre of 17.7 AU/mL in CLIA and a borderline titre of neutralizing
143 antibodies of 1:4 in enzyme linked neutralisation assay (ELNA)

144 Humoral immune responses increased in the course of disease and yielded high values of
145 1320, > 2080 and 1750 AU/mL in chemiluminescent immunoassay (CLIA) and >1:32 in
146 ELNA, on the days 124, 182 and 205, respectively. Although antibodies increased to positive
147 activities at day 124 and were maintained, IgG avidity did not mature over time, as the RAI
148 showed no significant increase and stayed in the low range <20%.

149 The analysis via immunoblot disclosed Spike 1 (S1) and the dedicated receptor-binding-
150 domain (RBD) as the main epitopes of the IgG antibodies in the patient's sera, whereas no
151 IgG antibodies could be detected against the region Spike 2 (S2) or the nucleocapsid. No
152 specific IgA antibodies were detected.

153 **Table 1:** Evaluation of antibody responses at different time points.

| day | CLIA (AU/mL) | ELNA (titre) | Blot IgG (AU/mL) | Activity (U/mL) | RAI (%) |
|-----|--------------------|------------------|---------------------------------------|-----------------|---------|
| 102 | positive (17.7) | borderline (1:4) | negative | 1.28 | n.d. |
| 124 | positive (1320.0) | positive (1:32) | positive S1 (209), RBD (405) | 106.7 | 2.9 |
| 182 | positive (>2080.0) | positive (>1:32) | positive S1 (294), RBD (459) | 145.5 | 17.4 |
| 250 | positive (1750.0) | positive (1:32) | positive S1 (229), RBD (353), S2 (85) | 69.1 | 22.9 |

154 Overview of the patient's serological data from day 102, 124 and 182. The used diagnostic
155 tools were the LIAISON® SARS-CoV-2 TrimericS IgG (DiaSorin S.p.A., Saluggia, Italy)
156 (LIAISON), an Immunoblot called ViraChip® assay (Viramed, Munich, Germany), Avidity and
157 an in-house Enzyme-Linked Neutralization Assay (ELNA) (Sonnleitner et al., 2021b). The
158 data obtained from LIAISON® SARS-CoV-2 s1/s2 IgG CLIA assay are standardized
159 according to the WHO criteria. CLIA ... chemoluminescent immunoassay; AU/mL ... arbitrary
160 units/mL; ELNA ... enzyme-linked immunosorbent assay; S1 ... Spike 1; RBD ... receptor-
161 binding-domain; RAI ... relative avidity index (formula: IgG concentration with chaotropic
162 agent/IgG concentration with PBS).

163

164 **SARS-CoV-2 specific T-cell response**

165 On day 193 no IFN γ -producing SARS-CoV-2-specific immune cells could be detected in the
166 ELISpot assay (SI = 0.86), although a significant positive reaction against pokeweed mitogen
167 was demonstrated (mean of 213 SFU in the positive control versus mean of 1.4 SFU in the
168 negative control and mean 1.2 SFU cells in the SARS-CoV-2-antigen stimulated wells).

169 **Humoral immune response did not clear SARS-CoV-2 infection**

170 The Ct values and numbers of PFU/mL were significantly lower after day 124. The high titre
171 of IgG antibodies of 1320 AU/mL and a neutralizing antibody titre of 1:32 analysed by our in-
172 house assay on day 124 was associated with a significant reduction of the viral load but
173 could not clear the infection.

174 We therefore decided to undertake a detailed examination of the specific genetic background
175 of the virus population present including potential intra-host mutational dynamics.

176 **Mutational intra-host dynamics**

177 Over the study period of 221 days, 14 haplotypes were sequenced out of naso-pharyngeal
178 samples. The sequences were obtained on day 73, 93, 109, 129, 133, 136, 143, 158, 164,
179 171, 182, 192 and day 207 of the patient’s prolonged infection. The timeline of infection and
180 a chronology of intra-host non-synonymous mutational events are given in **Figure 4**.

181 The calculation of the pairwise mutation distances did not show higher intra-host evolutionary
182 rates in contrast to overall evolutionary rates of about $(8-9) \times 10^{-4}$ substitutions per year (Day
183 et al., 2020; Dearlove et al., 2020). The pairwise distance between day 73 and day 171 was
184 4.4×10^{-4} in 98 days, implying a nucleotide substitution rate of 7.5×10^{-4} .

185 All NGS sequences were shown to belong to the prevalent Pangolin lineage B.1.1. and the
186 Nextstrain clade 20B.

187 We became aware of the prolonged viral shedding after about two months and started to
188 regularly sequence the patient’s subsequent swabs as of day 73. The sequence derived
189 from the swab of day 73 showed 18 mutations in comparison to the reference genome
190 Wuhan (GenBank: MN908947.3, RefSeq: NC_045512.2), the sequence on day 171 had 26
191 substitutions which increased to 29 on day 207. A listing of all persistent and temporary non-
192 synonymous mutations that the strain has accumulated intra-host and their concordance to
193 variants of concern and variants of interest are given in **Table 2**. Overall, 22 non-
194 synonymous mutations evolved over the study period of 221 days (7 months). Eleven (50%)
195 of these non-synonymous mutations were persistent, whereas 11 (50%) occurred temporarily
196 and were replaced by the wildtype or a different substitution. Seventeen of the 22 non-
197 synonymous mutations evolved in the region coding for spike, eight of those were temporary.
198 Seventeen of the 22 acquired non-synonymous mutations (77.3%) were issued as immune
199 escape mutations by the WHO ([https://www.who.int/en/activities/tracking-SARS-CoV-2-](https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)
200 [variants/](https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)) (**Figure 4**). Among the persistent non-synonymous mutations in spike, as many as
201 88.2% are found in various VOIs or VOCs (**Table 2**). All those genetic changes occurred
202 after the development of high antibody titres.

203 One region continuously showed diffuse mutational changes, with changing temporary
204 adaptations of substitutions and deletions, which was ORF1b: position 709 – 716.

205 An overview of the intra-host mutational development of SARS-CoV-2 during the study
206 period of 221 days is given in **Table 3** and **Figure 3**.

207

208 **Table 2: Listing of all persistent and temporary non-synonymous mutations that the**
209 **strain has accumulated over the 7-months study period.**

| | n total | VOC/VO | | n in spike | VOC/VO | |
|--------------------------------------|---------|--------|------------|------------|--------|------------|
| | | I | [%] | | I | % |
| Acquired non-synonymous mutations: | 22 | 17 | [77.3] | 17 | 15 | [88.2] |
| Persistent non-synonymous mutations: | 11 | 8 | [72.7] | 9 | 8 | [88.9] |
| temporary non-synonymous mutations: | 11 | 9 | [81.8] | 8 | 7 | [87.5] |

210 n total ... number of all non-synonymous intra-host acquired mutations; n in spike ... number
211 of all non-synonymous intra-host acquired mutations in the region coding for spike; VOC/VOI

212 ...number of mutations that are found in comparable expression in a variants of concern
 213 (VOC) or a variant of interest (VOI).

214 **Table 3:** Overview of A) substitutions and B) deletions in the SARS-CoV-2 genome over a
 215 seven-months study period in an immunocompromised patient.

| polymorphic | | temporary mutations | |
|------------------|--------------------------|-------------------------------|----------------------------------|
| A) substitutions | strain-specific sub. | acquired sub. | acquired and lost sub. |
| | | <u>S:E484K* (day 136) β δ</u> | |
| ORF1b:D708A | E:L73F | o | ORF8:Y73C* (day 73) α |
| ORF1b:K709X | N:R203K | S:N354K (day 158) | S:T716I* (day 73) α |
| ORF1b:Y710X | N:G204R | S:R346I* (day 164) | ORF3a:V255X (day 73) |
| ORF1b:Y710L | ORF1a:L758V | ORF1a:T3284I (day 171) | S:A831V (day 117) |
| ORF1b:V711D | ORF1a:P971S | S:D950N* (day 171) δ γ | <u>S:Y145X (day 117 - 123) o</u> |
| | | | S:N501Y* (day 123) α β δ |
| ORF1b:V711X | ORF1a:M3221I | S:P681H*(day 182) α o | <u>o</u> |
| ORF1b:R712X | ORF1a:V3976F | | <u>S:Y144H (day 129) o</u> |
| | ORF1b:P314L* α δ | | |
| ORF1b:V711E | γ | | S:E484Q (day 129) o |
| | | | S:del(9) 22287* (day 136) |
| ORF1b:R712X | ORF1b:S598I | | β |
| ORF1b:L714X | ORF1b:P1000L* δ γ | | N:S235F* (day 136) α |
| ORF1b:I2568X | S:D614G* α β δ γ | | S:H655Y* (day 158) δ o |
| | S:A879S | | |
| polymorphic | | temporary mutations | |
| B) deletions | strain-specific del. | acquired del. | |
| ORF1b:K709- | ORF1a:A1204- | ORF1b:L714- (day 158) | |
| ORF1b:Y710- | ORF1a:E1205- | <u>S:L141- (day 164) o</u> | |
| ORF1b:V711- | ORF1a:I1206- | <u>S:G142- (day 164) o</u> | |
| ORF1b:R712- | ORF1a:P1207- | <u>S:V143- (day 164) o</u> | |
| ORF1b:N713- | ORF1a:K1208- | <u>S:Y144-* (day 171) o</u> | |
| ORF1b:L714- | ORF1a:E1209- | | |
| ORF1b:Q715- | ORF1a:E1210- | | |
| ORF1b:H716- | | | |

216 Column 1 shows genetic variations in ORF1b, a region with repeated changes between
 217 substitutions and deletions, i.e. polymorphic substitutions and deletions.. Column 2 shows
 218 substitutions and deletions in comparison to the reference genome Wuhan (GenBank:
 219 MN908947.3, RefSeq: NC_045512.2), strain-specific, manifested since the beginning of the
 220 infection and maintained throughout the seven-months study period. Column 3 is a
 221 chronology of all mutations acquired by SARS-CoV-2 during the intra-host evolutionary
 222 process. * ... mutations of concern or mutations which are described in the context of
 223 immune escape. Column 4 shows temporary mutational events which occurred once and did
 224 not occur any more in the following sequence. sub. ... substitutions; del. ... deletions α ...
 225 mutations are described for the Alpha variant B.1.1.7; β ... Beta variant B.1.351; δ ...
 226 Gamma variant B.1.1.28.1; γ ... Delta variant B.1.617.2; o ... Omicron variants B.1.1.529).
 227 Underlined mutation sites are also found in the Omicron variant, but with a different
 228 substitution.

229

230

231 **Figure 2:** Localization of the substitutions and deletions acquired by the strain
 232 EPI_ISL_2106199 of clade 20B in the course of the prolonged infection of an
 233 immunocompromised patient. All acquired and preserved genetic adaptations occurred in the
 234 regions ORF1a (n = 1), ORF1b (n = 1) and spike (n = 9).

235

236 Chronology of acquired mutations

237 In the underlying clinical case the substitutions emerged in the following chronological order:

238 S:Y144- emerged immediately after the increase of the specific antibody titre at day 117 as a
239 temporary mutation, followed by E484Q (day 129), which could not assert itself against
240 E484K and was displaced at least 7 days later (day 136). Furthermore, we found the
241 substitutions S:N354K (day 158, 164, 171 und 182), S:R346I (day 164) and ORF1a:T3284I
242 (day 171), S:D950N (day 171) as well as the prominent S:P681H on day 182 (Fig. 2). Three
243 of the six acquired substitutions (50%) have already been described as typical mutations
244 acquired by diverse variants of concern.

245 Thirteen of the seventeen acquired substitutions (76.5%) occurred in the genomic region
246 coding for spike, and one each in the regions coding for ORF1a:T3284, ORF3a:V255X (day
247 73), ORF8:Y73C* (day 73) and N:S235F* (day 136) (**Fig. 2**).

248 Other mutations appeared temporarily and were subsequently replaced by the wildtype
249 variant. Five hitherto undescribed temporary mutations were observed on the days 73
250 (ORF3a:V255X), 117 (S:A831V), 117 - 123 (S:Y145X), day 129 (S:Y144H), as well as on
251 day 129 (S:E484Q, S:Y144H) (Fig. 3).

252 Six temporary mutations have already been described previously, all of them prominent
253 variations known in the context of variants of concern ([https://covariants.org/shared-](https://covariants.org/shared-mutations)
254 [mutations](https://covariants.org/shared-mutations); Center for Disease Control and Prevention;
255 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>): ORF8:Y73C and
256 S:T716I evolved in the early stage of the infection and are described in the context of the
257 Alpha variant, S:N501Y, known from the Alpha, Beta, Gamma and Omicron variant,
258 S:del(9) described in the Beta variant, N:S235F, known as a typical substitution of the Alpha
259 variant and S:H655Y, described in the context of the Beta as well as the Omicron variants.
260 All these temporarily recurring mutational events did not establish permanently but
261 disappeared again or were dominated again by the wildtype variant. **Figure 3** shows the
262 acquired und temporarily acquired mutations of strain EPI_ISL_2106199 in the region coding
263 for spike and demonstrates the high concordance of the acquired adaptations with described
264 variants of concern, above all the Alpha and the Omicron variant (15/17; 88.2%). **Figure 3**
265 represents the adaptations in the region coding for spike. Further mutations in the genome
266 were ORF1a:T3284I (day 171), ORF8:Y73C (day 73), ORF3a:V255X (day 73), N:S235F
267 (day 136), ORF1b:L714- (day 158). Thirteen of the 17 mutations (76.5%) acquired in the
268 course of the prolonged infectious phase are already described mutations in variants of
269 concern. Ten of the 17 spike mutations occur in a similar or identical way in the Omicron
270 variant (58.8%). The non-synonymous mutations S:del143, S:del144, S:N501Y, S:H655Y
271 and S:P681H were developed in identical form in the Omicron variant. Further non-
272 synonymous mutations occurred at the amino acid positions S:142, S:144, S:145, S:484
273 (twice) in strain EPI_ISL_2106199 as well as in the Omicron variant, which, however, led to
274 different expressions (S:del142 instead of S:G142D, temporarily both S:Y144H versus
275 S:144del and S:Y145X versus S:145del as well as S:E484Q and S:E484K instead of
276 S:E484A). Overall, 76.5% of all mutations and 88.2% of the spike mutations acquired by
277 strain EPI_ISL_21061 convergently evolved in other variants of concern, mainly in the Alpha
278 and the Omicron variant.

279

280

281 **Figure 3:** The acquired and temporarily acquired mutations of strain EPI_ISL_2106199 in the
282 course of a seven months lasting course of infection in an immunocompromised person in
283 the region coding for spike. Overall, 17 persistent or temporary spike mutations were
284 evolved, whereas 9 (52.9%) turned out to be temporary and were subsequently replaced by
285 the wild-type variant. * ... temporary mutations; S1 ... spike 1; S2 ... spike 2; hr ... heptad
286 repeat; RBD ... receptor binding domain; The mutations marked in orange are also found in
287 the Omicron variant (B.1.1.529) in similar or identical expression (10 out of 17), mutations
288 marked in red are found in other variants of concern (3 of 17; 17.6%). Thirteen of the 17
289 mutations (76.5%) acquired in the course of the prolonged infectious phase are already
290 described mutations in variants of concern.
291

292 Overall, SARS-CoV-2 developed eleven persistent mutations during the study period of 140
293 days as well as eleven temporary mutational events. The chronology of intra-host mutational
294 events is displayed in **Figure 4**.

295

296

297 **Figure 4:** Chronology of the emergence of intra-host mutations in an immunocompromised
298 patient with adequate humoral and lacking cellular immune response. The study period
299 comprised 140 days of almost permanent viral shedding. High-quality next-generation
300 sequences could be obtained at 14 time-points during the seven-month study period (starting
301 on day 73, ending on day 207 with the last SARS-CoV-2 positive swab) and disclosed the
302 chronological development of mutational events of SARS-CoV-2 as an answer to a unilateral
303 immune response with strong antibody answer but lack of specific T-cells.

304

305 In the first swab sample, whole genome sequencing did not detect any spike mutations in the
306 investigated strain compared to the reference genome. First spike variants appeared as
307 E484K on day 133 as a heterozygotic mutation in 41.3% of the targeted reads. On day 136
308 the proportion of E484K increased to 76% and, after more than seven days (day 143) the
309 new variant dominated with 100%, but decreased to 76.8% again on day 158. On day 171
310 the spike variant P681H was observed for the first time with a proportion of 24% and
311 dominated within a couple of weeks reaching 100% on day 182.

312 Three of the six acquired substitutions (50%) are previously described substitutions of
313 immune escape variants, namely: S:E484K, S:D950N and S:P681H.

314

315

316 **Figure 5:** Chronology of the appearance of convergent intra-host mutations in a strain of the
317 clade B.1.1., as they have been proven in identical form in the variants of concern. α ...
318 mutations are described for the Alpha variant B.1.1.7; β ... Beta variant B.1.351; δ ...
319 Gamma variant B.1.1.28.1; γ ... Delta variant B.1.617.2; \omicron ... Omicron variant B.1.1.529. The
320 red line graph shows the mean frequency of all mutations at a given day. The occurrence of
321 mutations did not occur straight-line, but in a fluctuating course, with frequent replacement by
322 the wildtype variant.

323

324 **The fluctuating occurrence of adaptive mutations**

325 The emergence of adaptive mutations did not occur in a linear but fluctuating fashion.
326 Frequently, new mutations arose at a certain time point to be later replaced by the wildtype
327 variant, again. As shown in **Figure 5**, the mutation rate shows an oscillating course with

328 peaks around day 125, increasing until day 182. Simultaneously, the viral load decreased
329 continuously until the patient had several consecutive negative SARS-CoV-2 qPCR tests
330 since day 232 and is therefore considered to be cured from COVID-19.
331

332 **Intra-host evolutionary history**

333 The intra-host evolution of the strain EPI_ISL_2106199 from day 73 and the quasi-species
334 arising from it in the course of the intra-host evolution form a distinct clade in the consensus
335 tree and group together. The clade is embedded in a random composition of complete
336 Austrian strains and variants of concern found in Europe and described and uploaded to
337 GISAID platform in the same study period from January to May 2021 (**Figure 6**). Early
338 Austrian sequences of the Omicron variant from December 2021 were included
339 subsequently.

340

341

342 **Figure 6:** Outgroup-routed consensus tree based on 40 SARS-CoV-2 whole genome
343 sequences with 29,806 nucleotide sites. The section highlighted in red shows the
344 monophyletic clade of variants newly formed in an immunocompromised patient, embedded
345 in prominent variants of concern and typical Austrian strains sequenced in the same
346 investigation period, downloaded from GISAID and completed by early Austrian sequences
347 of the Omicron variant in December 2021. Numbers at nodes indicate bootstrap support
348 values (only values > 50 are shown).
349

350

351

351 **DISCUSSION**

352 In this unique case report we described the dynamics of intra-host mutational events in an
353 immunocompromised patient during a seven-months period of prolonged viral shedding and
354 proven infectivity. We considered the possible influence of a quantitatively strong but
355 regarding binding capacities probably functionally ineffective humoral antibody response and
356 a lacking cellular immune response on the site-directed mutagenesis of SARS-CoV-2.

357 Our sequencing approach resulted in high-confidence variant identification and robust
358 genome-wide coverage and enabled the establishment of a chronology of immune escape
359 mutations. In addition, previously undescribed site-directed base-exchanges, found in the
360 regions ORF1a and b ($n = 2$; ORF1a:T3284I, ORF1b:L714-), ORF3a (ORF3a:V255X) and spike
361 protein ($n = 2$; S:N354K, S:A831V), were described here. Four different well-established
362 serological methods gave insights into the humoral immune response and demonstrated the
363 inability to clear the SARS-CoV-2 infection despite positive antibody responses. This may be
364 due to the relatively low neutralizing ability of the detected IgG which is also supported by the
365 low avidity of the specific IgG and impaired avidity maturation over time. Administration of
366 IVIG was not able to enhance the clearance of SARS-CoV-2. Cellular immunity was
367 diminished in this patient and the lack of adapted T cell-mediated immune defence may have
368 contributed to the inefficient clearance.

369 The substitution rate for SARS-CoV-2 was estimated as $(8-9) \times 10^{-4}$ nucleotides per site per
370 year (32). This is comparable to previously reported substitution rates of SARS-CoV ($8.0-$
371 23.8×10^{-4}) (33) and MERS-CoV (11.2×10^{-4}) (34, 35) and comparable to the reported
372 substitution rates for Influenza A ($4-5 \times 10^{-3}$) and Influenza B (2×10^{-3}) virus in the
373 haemagglutinine gene (36). From this substitution rate it can be estimated that SARS-CoV-2
374 undergoes about one genetic change every other week (32). In comparison, the nucleotide
375 substitution rate per site and per year for Ebola (EBOV Makona) is estimated to be $\sim 1.2 \times 10^{-}$

376 ³ (37) and for HIV-1 (3.21-4.06) * 10⁻³ (38). Interestingly, the evolutionary rate stayed
377 constant throughout the first months of infection but decreased slightly after the increase of
378 specific antibodies on day 124. We did not find elevated intra-host substitution rates
379 compared to the general rate reported for SARS-CoV-2 (32). This unaltered intra-host
380 evolutionary rate compared to the global average evolutionary rate suggests that these
381 mutations in an immunocompromised patient, driven by specific antibodies, do not lead to
382 more frequent random genomic changes, but on the contrary to very specific targeted ones.

383 We assume that the presence of specific antibodies forced directional selection on retaining
384 or regaining infectiousness and thereby strongly favoured directional mutations at particular
385 sites, acting as immune escape mutations.

386 E484K, a substitution in the receptor binding domain (RBD) appeared early in the course of
387 the infection and is described to impair neutralization resistance (39), potentially
388 compromising vaccines effectiveness (4, 6, 40-47). E484K is a well-established distinction of
389 the variants of concern (VOC) B.1.1.7 with E484K, P.1, P.2, B.1.315, B.1.525, B.1.526 as
390 well as B.1.617.1 (Center for Disease Control and Prevention;
391 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>). At the same position
392 E484, both subtypes of the Omicron variant have formed the alternative substitution alanine
393 A (Center for Disease Control and Prevention; <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>). On day 158, the Omicron-specific mutation S:H655Y (48, 49)
394 could also be detected as a temporary substitution. A further genomic change in the region
395 coding for spike was identified on position S:N354K on day 158 and had never been
396 described before. R346I was detected in the sequence of day 164. This mutation was
397 previously described as a reaction of SARS-CoV-2 after monoclonal antibody treatment,
398 seeming to maintain ACE2 binding activity (50) and has also developed in the VOI Mu, 21H,
400 B.1.621 (<https://covariants.org/shared-mutations>; Center for Disease Control and Prevention;
401 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>).

402 S:D950N arose around day 171 and is as adaptive mutation assigned to the Gamma and
403 Delta variant (Center for Disease Control and Prevention;
404 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>).

405 The substitution P681H was observed for the first time in the sequence of day 171, whereby
406 the amino acid histidine (H) first appeared as a polymorphism to become the dominant and
407 finally fixed variant in the course of the next ten days. This transformation from proline (P) to
408 histidine is relatively well studied and implicates a modification in the neighbouring furin
409 cleavage site at the junction of the spike protein receptor-binding (S1) and fusion (S2)
410 domains (51).

411 Another major transformation of the spike protein is the deletion of the amino acids 141 to
412 144. The deletions Y144/145- on the edge of the spike tip are modifications described in the
413 VOC B.1.1.7 as the recurrent deletion region 2 (rdr2), occurring repeatedly in SARS-CoV-2
414 variants (9, 10).

415 In our case, the deletions were extended to three more deleted positions on S:141, 142 and
416 143. S:143del is another analogy to the Omicron variant B.1.1.592.

417 Nine permanent mutations were found in the spike-coding region. More precisely, four are
418 located in the N-terminal domain (S:L141-, S:G142-, S:V143-, S:Y144-), three in the
419 receptor-binding domain (S:R346I, S:N354K and S:E484K), both parts of S1 and three are
420 positioned in the region encoding for S2, namely P681H in the immediate neighbourhood of
421 the furin cleavage site and S:D905N near heptad repeat 1 as part of the fusion core region.

422 Of the eleven acquired adaptive mutations, only two were found outside the spike-coding
423 regions, namely L714- in ORF1b (day 158) and T3284I in ORF1a (day 171). ORF1a and
424 ORF1b are coding regions for non-structural proteins (nsp) (52). ORF1a:T3284I is located in
425 the region encoding for nsp5. Nsp5 is regarded as the main protease, cleaves viral

426 polyprotein and works closely with nsp12 and nsp13. Together, nsp5, 12 and 13 represent
427 the replicase machinery (52-54). ORF1b:L714- is a deletion in the region coding for nsp13,
428 the enzyme helicase, a main component of membrane-associated replication-transcription
429 complexes (52, 55-57).

430 It is remarkable that nine of the eleven persistent mutations (81.8%) acquired in the course of
431 the prolonged infection had previously been described in the context of immune escape and
432 were assigned to diverse variants of concern. Our bioinformatic analyses revealed that 75%
433 of the novel mutations in our investigated strain also occur in variants of concern, whereas
434 the highest concordance was found between strain EPI_ISL_2106199 and the Omicron
435 variant (50%). Furthermore, we found dynamic mutational events with fluctuations between
436 the wildtype and the variational mutation. Nine of these temporary mutations (9 of 11; 81.8%)
437 have also been described in the context of variants of concern (Center for Disease Control
438 and Prevention; <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>). In the
439 close proximity of the acquired deletion in ORF1b:L714-, which manifested homozygously,
440 additional conspicuous polymorphic sequences in amino acid position ORF1b:708-716 were
441 found. We measured frequent changes in substitutions and deletions. This certainly left us
442 with the impression of mutational escape manoeuvres. Also, this hotspot in directional
443 mutations encodes for nsp13, the helicase.

444 We thus suggest that the accumulated mutations are results of an increased selection
445 pressure on spike, the key to entering the host cell. At the same time a second process takes
446 place intra-host, which exerts increased pressure and enforces continual reconstructions in
447 nsp13. The findings of these temporary mutations, which almost exclusively occurred in the
448 spike region, also fit this pattern very well.

449 We managed to isolate SARS-CoV-2 from swabs at different time points, which is further
450 evidence for the continuous viability of the virus over the study period, given the evolutionary
451 dynamics of the different sequences. The isolation success correlated negatively with the Ct
452 value, a fact that has already been observed in previous studies (22).

453 Treatment with Rituximab resulting in depletion of particularly memory and effector B cells by
454 targeting CD20 is known to cause impaired antibody responses (58-60). As naïve B cell
455 clones are less sensitive to Rituximab treatment due to their lower expression of CD20, a
456 robust immune response can also be assumed for those patients. Immunosuppressive
457 therapy as well as the lymphoma disease itself may have diminished the T cellular axis of
458 immune defence against SARS-CoV-2, which targets infected cells, and loss of control by
459 cytotoxic T cells may have caused the ongoing replication of SARS-CoV-2 in naso-
460 pharyngeal epithelial cells (61, 62). Impaired T cell help may have contributed to the
461 inefficient antibody maturation.

462 Meanwhile, there are more studies that shed light on the evolution of immune escape
463 variants in immunocompromised patients and support the results of our study (12, 63-
464 69). (12, 63-69) Nonetheless, our study not only shows the accumulation of an unusually high
465 number of immune escape mutations in a single patient, which to a strikingly high degree
466 evolved in parallel in various variants of concern. The chronology of mutation events during
467 seven months of infection shows a rapid accumulation of non-synonymous mutations which
468 in part were persistent, in part temporary or even repeatedly acquired and lost.

469 In summary, our case report documents the medical phenomenon of persisting SARS-CoV-2
470 infection in an immunocompromised patient with impaired humoral and cellular immune
471 response. Potential interference of specific antibodies led to a significant reduction in the viral
472 load, but at the same time generated sophisticated escape mechanisms while the cell-
473 mediated immune defence for eradication of the infection is missing. With the aid of NGS, we
474 witnessed the directed mutational changes of SARS-CoV-2, probably facilitated by
475 insufficient humoral immune defence. This led to the formation of highly specific virus
476 variants, highlighting the regions exposed to the highest intra-host selective pressure. Based

477 on this observation one may hypothesize that immunocompromised patients pose a
478 particular risk to establish a source of immune escape mutants of SARS-CoV-2. Our study
479 also underlines the importance to protect these patients from SARS-CoV-2 infection by
480 modified vaccination strategies as well as to reinforce vaccination efforts to increase herd
481 immunity in general. Most importantly, the study points out the convergent evolution of
482 specific mutations in SARS-CoV-2, both in VOCs, VOIs and intra-host in the strain we
483 studied (EPI_ISL_2106199). Those specific, convergently evolving mutations reveal those
484 neuralgic positions in the SARS-CoV-2 genome that on the one hand represent its highest
485 fitness advantage, but on the other hand also uncovers its highest vulnerability and should
486 be considered as the probably most important points of attack in future vaccine and
487 therapeutics development.

488

489 **METHODS**

490 **Immunological diagnostics**

491 **CLIA SARS-CoV-2 TrimericS IgG**

492 Serological tests were performed using the LIAISON® SARS-CoV-2 TrimericS IgG (DiaSorin
493 S.p.A., Saluggia, Italy) (LIAISON), an Immunoblot called ViraChip® assay (Viramed, Munich,
494 Germany) and an in-house enzyme-linked neutralization assay (ELNA) (14) at day 102, 124,
495 182 and 205 after the first positive PCR.

496 The LIAISON® SARS-CoV-2 TrimericS IgG is a CLIA (Chemiluminescent Immunoassay)
497 which detects IgG antibodies reactive with the spike protein (S1/S2 domain). The assay was
498 performed on the LIAISON® XL Analyzer according to the manufacturer's instructions and
499 gives the arbitrary units per ml (AU/mL) according to the WHO International Standards for
500 the Anti-SARS-CoV-2-immunoglobulin-binding activity (NIBSC 20-136).

501 **Microarray immunoblots**

502 The ViraChip® assay detects temporal antibody profiles of different immunoglobulin classes
503 against S1, S2, and nucleocapsid (N) as well as against N of the four nonSARS human
504 coronaviruses in a commercial, miniaturized 96 wells protein microarray. The ViraChip®
505 assay is a useful tool to identify the epitope-specificity of IgG and IgA in serum samples. The
506 quantitative antibody measurement was performed on a ViraChip® Scanner using ViraChip®
507 Software.

508 **Neutralization test**

509 Neutralization ability of antibodies was determined performing an in-house enzyme-linked
510 neutralization assay (ELNA) as described elsewhere (14).

511 **Anti-IgG-SARS ELISA**

512 Serum IgG antibodies against SARS-CoV-2 were determined by Serion agile SARS-CoV-2
513 ELISA with a sensitivity of 96.2% and a specificity of 100% according to manufacturer's
514 instructions (Virion/Serion, Wuerzburg, Germany). Antibody activities above 15U/mL were
515 considered positive.

516 **Anti-IgG-SARS-Avidity**

517 Relative avidity index (RAI) was determined by a modification of the Serion agile SARS-CoV-
518 2 IgG-SARS ELISA using 1M ammonium thiocyanate (NH₄SCN) as a chaotropic agent as
519 described previously (15-17). RAI values were considered as: RAI > 60% high avidity, 40% <
520 RAI < 60% as moderate, and RAI < 40% as low avidity in reference to other viral infections
521 (18).

522 **SARS-CoV-2 specific T cell response**

523 The ELISpot assay was performed using a commercially available precoated human SARS-
524 CoV-2-specific IFN- γ ELISPOT kit according to the manufacturer's protocol (Autolmmun
525 Diagnostika, GmbH, Germany; Cat.no. ELSP 5500). Peripheral blood was collected into
526 tubes coated with lithium-heparin (Vacuette, Greiner bio-one, Austria). PBMCs were
527 separated from plasma and whole blood by gradient density (FicoLite[®] -H, Linaris,
528 Germany). After washing with phosphate-buffered saline (PBS), depleting erythrocytes
529 (RBD-Lyse Buffer Life Technologies, 1xRBC Lysis Buffer 200ml; Invitrogen eBioscience,
530 USA REF: 00-4333-57) and washing again with PBS, cells were counted and resuspended in
531 x-vivo medium (X-VIVO TM-10 Serum-free hematopoietic cell medium; BEBP02-055Q,
532 Lonza, Switzerland).

533 Briefly, a total of 2×10^5 PBMCs were incubated in duplicate with x-vivo as a negative
534 control, pokeweed mitogen (Autolmmun Diagnostika GmbH, Germany) as a positive
535 control, 15-20mer peptide pools for SARS-CoV-2 (Autolmmun Diagnostika GmbH, Germany)
536 and PanCorona (Autolmmun Diagnostika GmbH, Germany) for the four nonSARS human
537 coronaviruses 229E, HKU1, NL63 and OC43 as a control of possible cellular cross-reactive
538 responses. After incubation at 37° C for 20 hours in a sterile and humidified atmosphere,
539 plates were washed with washing buffer (Autolmmun Diagnostika GmbH, Germany) and
540 stained with the kit-specific reagents according to the manufacturer's protocol. Plates were
541 then washed several times under running water and dried overnight. Spot forming units
542 (SFU)/100.000 cells were counted using an automated AID ELISPOT reader system
543 (Autolmmun Diagnostika GmbH, Germany).

544 The assessment criteria for the ELISpots were a minimum of 50 SFU in the positive control
545 and a maximum of 10 SFU in the negative control according to the manufacturer's definitions
546 (19, 20). When those criteria were fulfilled, the stimulation index (SI) was calculated by
547 dividing the mean SFU numbers in the antigen-specific wells with the mean SFU numbers of
548 the negative control. The test was assessed negative with an $SI < 2$ according to previous
549 determination of the cut-off by well-defined pre-pandemic PBMC samples and by PBMCs
550 from SARS-CoV-2-naive individuals. The test was suggested to be poorly reactive with an SI
551 between 2 and 7 and reactive with an $SI \geq 7$ as defined by the manufacturer (19). According
552 to standardized laboratory procedures, in each assay, a standard laboratory control sample
553 of a high-reactive and a non-reactive PBMC sample, respectively, was run to determine inter-
554 assay-variations. Only assays with less than two standard deviations of the high-reactive and
555 the non-reactive PBMC control sample, respectively, were defined valid.

556 **Sample collection**

557 Nasopharyngeal swabs were taken in a standardized way in home quarantine in the context
558 of primary care by a medical co-worker.

559 **RNA extraction**

560 Nucleic acids were isolated using the MagMAX[™]-96 Total RNA Isolation Kit (Thermo Fisher
561 Scientific, Waltham, Massachusetts, USA; Cat. No. AM1830). Briefly, 200 μ l PBS were taken
562 from patient swab sample and mixed with 265 μ l binding buffer, 5 μ l proteinase K (20mg/mL)
563 and 5 μ l extraction control (Thermo Fisher Scientific, Waltham, Massachusetts, USA; Cat.
564 No. AM1830) according to the KingFisher[™] extraction protocol for 200 μ l sample volume
565 (Thermo Fisher Scientific, Waltham, Massachusetts, USA). After incubation at room
566 temperature for at least 15 minutes, samples were transferred from tubes into 96-well
567 KingFisher deep well plates (Thermo Fisher Scientific, Waltham, Massachusetts, USA)
568 containing 280 μ l isopropanol and 2 μ l Mag-Bind particles per well, using a KingFisher[™] Flex
569 purification system (Cat. No. 5400620).

570 **rtPCR**

571 qPCR extracts were tested for SARS-CoV-2 by qRT-PCR using the Bio-Rad CFX96 system
572 (Bio-Rad, Germany) with a LightMix Modular Assay kit in accordance with the modified

573 Charité guidelines (Corman et al., 2020). 10µL of extracted RNA were added into 15µL 4x
574 Reliance One-Step Multiplex Supermix (Bio-Rad, Germany). Each 15µL mastermix
575 contained 12.5µL buffer solution, 0.25µL enzyme mix, 1.75µL of nuclease-free water and
576 0.5µL primer probe wHCoV (E-Gene, as well as N-Gene and RdRp-Gene for confirmation).
577 Reactions were incubated at 55° C for 5 min and 95° C for 5 min in order to conduct reverse
578 transcription of viral RNA, sample denaturation and enzyme activation. These steps were
579 followed by PCR-amplification including 45 cycles at 95° C for 5 s, 60° C for 15 s and 72° C
580 for 15 s. Cooling was implemented at 40° C for 30 s. Results were interpreted based on the
581 Second Derivative Maximum (SDM) method. Positive results were confirmed by RdRp and N-
582 gene (21), samples with an initial Ct value lower than or equal to 37 were assigned to
583 repeated testing including extraction. A Ct value higher than 40 was considered negative.
584 Quantification of the viral load in the swabs was calculated via size standards of 1, 10, 100
585 and 1000 plaque-forming units (PFU)/mL. Standardization of viral stocks was carried out by
586 virus titration. Isolation was performed on VeroB4 cells as described elsewhere (22).

587 **Virus titration**

588 Confluent VeroB4 cells were cultured in Medium199 including 5% FCS in T75 tissue culture
589 flasks (Sarstedt, Germany) and transferred into 96-well tissue culture plates (Sarstedt,
590 Germany). Passage 1 isolates of SARS-CoV-2 were thawed from -80° C freezer and titrated
591 from 1:10 to 1:10⁻¹² in U-shaped 96-well plates (Greiner, Germany) and pipetted into each
592 corresponding well of the 96-well tissue culture plate. Plates were incubated at 36° C. Three
593 days post infection, incubation was stopped by gently removing the supernatant, washing the
594 cells three times with PBS and fixing cells in 1:1 ice-cold acetone-methanol. For easier
595 optical evaluation, cells were dyed by crystal violet staining and tissue culture infectious dose
596 of 70% (TCID₇₀) and PFU were calculated (Ramakrishnan, 2016).

597 **Whole genome sequencing and mutational analysis**

598 Libraries were prepared according to the Ion AmpliSeq™ SARS-CoV-2 Research Panel
599 (ThermoFisher, USA), library construction and sequencing protocol with the Library Kit Plus
600 (Thermo Fisher Scientific, Waltham, Massachusetts, USA; Cat. No. 4488990). The
601 Amplicons were cleaned up with AMPure XP beads (Beckman Coulter, Germany) with a 1:1
602 ratio. The libraries were quantified using the Ion Library TaqMan™ Quantitation Kit (Cat. No.
603 4468802), normalizing, pooling and sequencing was performed using an Ion Torrent™ S5
604 Plus. Ion Torrent Suite software (v 5.12.2) of the Ion S5 sequencer was used to map the
605 generated reads to a SARS-CoV-2 reference genome (Wuhan-Hu-1; GenBank accession
606 numbers NC_045512 and MN908947.3), using TMAP software included in the Torrent Suite.
607 The following plugins were used: Coverage Analysis (v5.10.0.3), Variant Caller (v.5.12.04)
608 for mutation calls both with “Generic □ S5/S5XL (510/520/530) □ Somatic □ Low Stringency”
609 and “Generic □ S5/S5XL (510/520/530) □ Germ Line □ Low Stringency” default parameters and
610 COVID19AnnotateSnpEff (v.1.0.), a plugin specifically developed for SARS □ CoV □ 2 that can
611 predict the effect of a base substitution. No ultra-deep sequencing was performed and only
612 mutations visible in the stated analysis methods were listed and rated.

613 FASTA files containing the raw reads were inspected for quality criteria (mapped, targeted,
614 filtered reads, mean depth and uniformity) using ThermoFisher Software. Multiple sequence
615 alignments were performed using Unipro UGENE (23) as well as MEGA X (Kumar et al.,
616 2018). The SARS-CoV-2 genomes were compared to the reference NC 045512.2-Wuhan-
617 Hu-1. Viral genome assembly and screening for distinct mutations was performed online
618 using nextstrain.org (<https://github.com/nextstrain/ncov/blob/master/defaults/clades.tsv>;
619 <https://clades.nextstrain.org/>). The identification of pangolin lineages was carried out using
620 Pangolin software, v.2.4.2. (<https://pangolin.cog-uk.io/>). The generated full-genome
621 sequences are available at GISAID EpiCoV ([https://gisaid.org/no.EPI_ISL_2106191-
622 21061201](https://gisaid.org/no.EPI_ISL_2106191-21061201)). Additional sequences of frequent Austrian strains and prominent variants of

623 concern, sequenced in the same study period, were retrieved from the GISAID EpiCoV
624 database (24) to calculate a consensus tree.

625 Indels were coded using 'simple indel coding' (25) as implemented in 2matrix v.1.0 (70).

626 The best-fit model of nucleotide substitutions (TIM2+F+I) was selected under the Akaike and
627 the Bayesian formation criteria using ModelFinder (71) as implemented in the PhyloSuite
628 Software package (26). Phylogenomic inference was based on a Maximum Likelihood (ML).
629 An ML tree with 5000 ultrafast bootstrap replicates was inferred in the IQ Tree plugin (27, 28)
630 of PhyloSuite.

631 **Bioinformatics CoV-Seq Workflow**

632 The frequency of the various mutations and the homology to the most widespread variants of
633 concern (Alpha-, Beta, Gamma- and Delta-variant) were investigated based on BAM files.
634 Reads from CoV-Seq samples were demultiplexed by using in-house tools. Reads
635 originating from human were filtered out by mapping against hg38 with bwa-mem 0.7.17 (29).
636 All reads not mapping to human were trimmed for adapters and quality by using Cutadapt
637 3.2(30). The trimmed reads were mapped with bwa-mem 0.7.17 to the SARS-CoV-2
638 reference MN908947.3 from the NCBI. Mutations were called using breseq 0.35.5 (31).
639 Graphics were created using *pandas* 1.2 for Python 3.

640 **Statistics**

641 Dichotomous data were evaluated by a chi-squared test or Fisher's exact in the case of
642 small group size ($n < 60$) (Microsoft® Excel®, Microsoft 395 MSO, Windows 10). A two-sided
643 significance level of $p < 0.05$ was used for determining statistical significance. After testing
644 for distribution (Kolmogorov-Smirnov-test), non-parametric continuous independent variables
645 were compared using Mann-Whitney-U test for each time point. Dependent non-parametric
646 variables were compared using Wilcoxon-rank test.

647

648

ACKNOWLEDGEMENT

We gratefully acknowledge the financial support of the Austrian Research Promotion Agency (FFG), Grant No. 889135. The authors report no potential conflict of interest. We also thank Ramona Polster, MSc, for excellent technical assistance, DDI Martin Lamprecht for valuable suggestions and all the kind colleagues from the routine diagnostics team of the Dr. Gernot Walder laboratory under the direction of BSc Viktoria Muehlmann and Mag. Hannes Mahl for great support.

AUTHOR CONTRIBUTION

Sissy Therese Sonnleitner: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology; Writing – original draft preparation. **Martina Prelog:** Writing – original draft preparation, editing; **Stefanie Sonnleitner:** Methodology, Writing – editing. **Eva Hinterbichler:** Investigation; Methodology; **Hannah Halbfurter:** Project administration. **Dominik B. C. Kopecky:** Visualization, Organization. **Giovanni Almanzar:** Methodology. **Stephan Koblmüller:** Conceptualization, Writing – editing, Funding acquisition. **Christian Sturmbauer:** Conceptualization, Writing – editing, Funding acquisition. **Leonard Feist:** Validation, Verification. **Ralf Horres:** Validation, Verification. **Wilfried Posch:** Validation, Supervision. **Gernot Walder:** Supervision.

ETHICAL APPROVAL

All clinical samples and data were collected for routine patient care and for public health interventions. The patient gave full written consent for the case to be attended and published. Ethical approval to use residual routinely taken serum samples for retrospective analyses was obtained by the Ethics Committee of the University Hospital Wuerzburg (no. 20201105_01).

COMPETING INTERESTS

The authors have no conflict of interest to declare.

DATA AVAILABILITY

The generated full-genome sequences are available at GISAID EpiCoV (https://gisaid.org/no.EPI_ISL_2106191-21061201).

References

1. Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. *Emerg Microbes Infect.* 2020;9(1):313-9. Epub 20200205. doi: 10.1080/22221751.2020.1725399. PubMed PMID: 32020836; PubMed Central PMCID: PMC7033720.
2. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis.* 2020;26(7):1470-7. Epub 20200621. doi: 10.3201/eid2607.200282. PubMed PMID: 32255761; PubMed Central PMCID: PMC7323562.
3. D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction number,. *Biosaf Health.* 2020;2(2):57-9. Epub 20200402. doi: 10.1016/j.bsheal.2020.03.004. PubMed PMID: 32835209; PubMed Central PMCID: PMC7148916.
4. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *Elife.* 2020;9. Epub 20201028. doi: 10.7554/eLife.61312. PubMed PMID: 33112236; PubMed Central PMCID: PMC7723407.
5. Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature.* 2021;593(7857):136-41. Epub 20210311. doi: 10.1038/s41586-021-03412-7. PubMed PMID: 33706364.

6. Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *Cell Host Microbe*. 2021;29(3):477-88.e4. Epub 20210127. doi: 10.1016/j.chom.2021.01.014. PubMed PMID: 33535027; PubMed Central PMCID: PMC7839837.
7. Müller K, Gierl P, Giebl A, von Buttlar H, Dobler G, Bugert JJ, et al. Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2. *J Clin Virol*. 2021;142:104912. Epub 20210716. doi: 10.1016/j.jcv.2021.104912. PubMed PMID: 34298379; PubMed Central PMCID: PMC8282447.
8. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*. 2021;592(7855):616-22. Epub 20210210. doi: 10.1038/s41586-021-03324-6. PubMed PMID: 33567448; PubMed Central PMCID: PMC8503938.
9. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol*. 2021;19(7):409-24. Epub 20210601. doi: 10.1038/s41579-021-00573-0. PubMed PMID: 34075212; PubMed Central PMCID: PMC8167834.
10. McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G, et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. *Science*. 2021;371(6534):1139-42. Epub 20210203. doi: 10.1126/science.abf6950. PubMed PMID: 33536258; PubMed Central PMCID: PMC7971772.
11. Aydililo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. *N Engl J Med*. 2020;383(26):2586-8. Epub 20201201. doi: 10.1056/NEJMc2031670. PubMed PMID: 33259154; PubMed Central PMCID: PMC7722690.
12. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *N Engl J Med*. 2020;383(23):2291-3. Epub 20201111. doi: 10.1056/NEJMc2031364. PubMed PMID: 33176080; PubMed Central PMCID: PMC7673303.
13. Kemp SA, Collier DA, Datir R, Ferreira I, Gayed S, Jahun A, et al. Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. *medRxiv*. 2020. Epub 20201229. doi: 10.1101/2020.12.05.20241927. PubMed PMID: 33398302; PubMed Central PMCID: PMC7781345.
14. Sonnleitner ST, Prelog M, Jansen B, Rodgarkia-Dara C, Gietl S, Schönegger CM, et al. Maintenance of neutralizing antibodies over ten months in convalescent SARS-CoV-2 afflicted patients. *Transbound Emerg Dis*. 2021. Epub 20210507. doi: 10.1111/tbed.14130. PubMed PMID: 33960696; PubMed Central PMCID: PMC8242897.
15. Almanzar G, Ottensmeier B, Liese J, Prelog M. Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate. *J Immunol Methods*. 2013;387(1-2):36-42. Epub 20120927. doi: 10.1016/j.jim.2012.09.008. PubMed PMID: 23022630.
16. Prelog M, Almanzar G, Rieber N, Ottensmeier B, Zlamy M, Liese J. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination. *Vaccine*. 2013;31(2):387-93. Epub 20121108. doi: 10.1016/j.vaccine.2012.10.105. PubMed PMID: 23142306.
17. Wratil PR, Stern M, Priller A, Willmann A, Almanzar G, Vogel E, et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. *Nat Med*. 2022. Epub 20220128. doi: 10.1038/s41591-022-01715-4. PubMed PMID: 35090165.
18. Kneitz RH, Schubert J, Tollmann F, Zens W, Hedman K, Weissbrich B. A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid. *BMC Infect Dis*. 2004;4:33. Epub 20040908. doi: 10.1186/1471-2334-4-33. PubMed PMID: 15355548; PubMed Central PMCID: PMC522815.
19. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. *Nat Rev Immunol*. 2006;6(5):417-23. doi: 10.1038/nri1840. PubMed PMID: 16622477.



20. Dennehy KM, Löll E, Dhillon C, Classen JM, Warm TD, Schuierer L, et al. Comparison of the Development of SARS-Coronavirus-2-Specific Cellular Immunity, and Central Memory CD4+ T-Cell Responses Following Infection versus Vaccination. *Vaccines* (Basel). 2021;9(12). Epub 20211207. doi: 10.3390/vaccines9121439. PubMed PMID: 34960185; PubMed Central PMCID: PMC8707815.
21. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* 2020;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000045. PubMed PMID: 31992387; PubMed Central PMCID: PMC6988269.
22. Sonnleitner ST, Dorigi J, Jansen B, Schönegger C, Gietl S, Koblmüller S, et al. An in vitro model for assessment of SARS-CoV-2 infectivity by defining the correlation between virus isolation and quantitative PCR value: isolation success of SARS-CoV-2 from oropharyngeal swabs correlates negatively with Cq value. *Viol J.* 2021;18(1):71. Epub 20210407. doi: 10.1186/s12985-021-01542-y. PubMed PMID: 33827618; PubMed Central PMCID: PMC8025900.
23. Okonechnikov K, Golosova O, Fursov M, team U. Unipro UGENE: a unified bioinformatics toolkit. *Bioinformatics.* 2012;28(8):1166-7. Epub 20120224. doi: 10.1093/bioinformatics/bts091. PubMed PMID: 22368248.
24. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro Surveill.* 2017;22(13). doi: 10.2807/1560-7917.ES.2017.22.13.30494. PubMed PMID: 28382917; PubMed Central PMCID: PMC5388101.
25. Simmons MP, Ochoterena H. Gaps as characters in sequence-based phylogenetic analyses. *Syst Biol.* 2000;49(2):369-81. PubMed PMID: 12118412.
26. Zhang D, Gao F, Jakovlić I, Zou H, Zhang J, Li WX, et al. PhyloSuite: An integrated and scalable desktop platform for streamlined molecular sequence data management and evolutionary phylogenetics studies. *Mol Ecol Resour.* 2020;20(1):348-55. Epub 20191106. doi: 10.1111/1755-0998.13096. PubMed PMID: 31599058.
27. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol.* 2015;32(1):268-74. Epub 20141103. doi: 10.1093/molbev/msu300. PubMed PMID: 25371430; PubMed Central PMCID: PMC4271533.
28. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: Improving the Ultrafast Bootstrap Approximation. *Mol Biol Evol.* 2018;35(2):518-22. doi: 10.1093/molbev/msx281. PubMed PMID: 29077904; PubMed Central PMCID: PMC5850222.
29. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *bioinformatics.* 2009.
30. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet journal.* 2011.
31. Deatherage DE, Barrick JE. Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. *Methods Mol Biol* 1151. 2014.
32. Day T, Gandon S, Lion S, Otto SP. On the evolutionary epidemiology of SARS-CoV-2. *Curr Biol.* 2020;30(15):R849-R57. Epub 20200611. doi: 10.1016/j.cub.2020.06.031. PubMed PMID: 32750338; PubMed Central PMCID: PMC7287426.
33. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, et al. Moderate mutation rate in the SARS coronavirus genome and its implications. *BMC Evol Biol.* 2004;4:21. Epub 20040628. doi: 10.1186/1471-2148-4-21. PubMed PMID: 15222897; PubMed Central PMCID: PMC446188.
34. Cotten M, Watson SJ, Kellam P, Al-Rabeeah AA, Makhdoom HQ, Assiri A, et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. *Lancet.* 2013;382(9909):1993-2002. Epub 20130920. doi: 10.1016/S0140-6736(13)61887-5. PubMed PMID: 24055451; PubMed Central PMCID: PMC3898949.
35. Cotten M, Watson SJ, Zumla AI, Makhdoom HQ, Palser AL, Ong SH, et al. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. *mBio.* 2014;5(1). Epub 20140218. doi: 10.1128/mBio.01062-13. PubMed PMID: 24549846; PubMed Central PMCID: PMC3944817.

36. Bedford T, Riley S, Barr IG, Broor S, Chadha M, Cox NJ, et al. Global circulation patterns of seasonal influenza viruses vary with antigenic drift. *Nature*. 2015;523(7559):217-20. Epub 20150608. doi: 10.1038/nature14460. PubMed PMID: 26053121; PubMed Central PMCID: PMC4499780.
37. Holmes EC, Dudas G, Rambaut A, Andersen KG. The evolution of Ebola virus: Insights from the 2013-2016 epidemic. *Nature*. 2016;538(7624):193-200. doi: 10.1038/nature19790. PubMed PMID: 27734858; PubMed Central PMCID: PMC5580494.
38. Duchêne S, Ho SY, Holmes EC. Declining transition/transversion ratios through time reveal limitations to the accuracy of nucleotide substitution models. *BMC Evol Biol*. 2015;15:36. Epub 20150311. doi: 10.1186/s12862-015-0312-6. PubMed PMID: 25886870; PubMed Central PMCID: PMC4358783.
39. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe*. 2021;29(3):463-76.e6. Epub 20210208. doi: 10.1016/j.chom.2021.02.003. PubMed PMID: 33592168; PubMed Central PMCID: PMC7869748.
40. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science*. 2020;369(6506):1014-8. Epub 20200615. doi: 10.1126/science.abd0831. PubMed PMID: 32540904; PubMed Central PMCID: PMC7299283.
41. Ku Z, Xie X, Davidson E, Ye X, Su H, Menachery VD, et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. *Nat Commun*. 2021;12(1):469. Epub 20210120. doi: 10.1038/s41467-020-20789-7. PubMed PMID: 33473140; PubMed Central PMCID: PMC7817669.
42. Muik A, Wallisch AK, Sängler B, Swanson KA, Mühl J, Chen W, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science*. 2021;371(6534):1152-3. Epub 20210129. doi: 10.1126/science.abg6105. PubMed PMID: 33514629; PubMed Central PMCID: PMC7971771.
43. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*. 2021;593(7857):130-5. Epub 20210308. doi: 10.1038/s41586-021-03398-2. PubMed PMID: 33684923.
44. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. *Nat Med*. 2021;27(4):622-5. Epub 20210302. doi: 10.1038/s41591-021-01285-x. PubMed PMID: 33654292.
45. Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. *bioRxiv*. 2021. Epub 20210125. doi: 10.1101/2021.01.25.427948. PubMed PMID: 33501442; PubMed Central PMCID: PMC7836112.
46. Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, et al. SARS-CoV-2 escape. *bioRxiv*. 2020. Epub 20201228. doi: 10.1101/2020.12.28.424451. PubMed PMID: 33398278; PubMed Central PMCID: PMC7781313.
47. Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat Med*. 2021;27(4):620-1. Epub 20210208. doi: 10.1038/s41591-021-01270-4. PubMed PMID: 33558724.
48. Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. *Cell*. 2022. Epub 20220104. doi: 10.1016/j.cell.2021.12.046. PubMed PMID: 35081335; PubMed Central PMCID: PMC8723827.
49. Kim S, Nguyen TT, Taitt AS, Jhun H, Park HY, Kim SH, et al. SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues. *Immune Netw*. 2021;21(6):e38. Epub 20211223. doi: 10.4110/in.2021.21.e38. PubMed PMID: 35036025; PubMed Central PMCID: PMC8733186.


50. Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. *Nat Microbiol.* 2021;6(10):1233-44. Epub 20210921. doi: 10.1038/s41564-021-00972-2. PubMed PMID: 34548634; PubMed Central PMCID: PMC8543371.
51. Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR. Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop. *J Mol Biol.* 2020;432(10):3309-25. Epub 20200419. doi: 10.1016/j.jmb.2020.04.009. PubMed PMID: 32320687; PubMed Central PMCID: PMC7166309.
52. Rohaim MA, El Naggat RF, Clayton E, Munir M. Structural and functional insights into non-structural proteins of coronaviruses. *Microb Pathog.* 2021;150:104641. Epub 20201123. doi: 10.1016/j.micpath.2020.104641. PubMed PMID: 33242646; PubMed Central PMCID: PMC7682334.
53. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. *Methods Mol Biol.* 2015;1282:1-23. doi: 10.1007/978-1-4939-2438-7_1. PubMed PMID: 25720466; PubMed Central PMCID: PMC4369385.
54. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. *J Med Virol.* 2020;92(10):2249. Epub 20200802. doi: 10.1002/jmv.26234. PubMed PMID: 32881013; PubMed Central PMCID: PMC7435528.
55. Prentice E, Jerome WG, Yoshimori T, Mizushima N, Denison MR. Coronavirus replication complex formation utilizes components of cellular autophagy. *J Biol Chem.* 2004;279(11):10136-41. Epub 20031229. doi: 10.1074/jbc.M306124200. PubMed PMID: 14699140; PubMed Central PMCID: PMC7957857.
56. Prentice E, McAuliffe J, Lu X, Subbarao K, Denison MR. Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins. *J Virol.* 2004;78(18):9977-86. doi: 10.1128/JVI.78.18.9977-9986.2004. PubMed PMID: 15331731; PubMed Central PMCID: PMC514967.
57. Subissi L, Imbert I, Ferron F, Collet A, Coutard B, Decroly E, et al. SARS-CoV ORF1b-encoded nonstructural proteins 12-16: replicative enzymes as antiviral targets. *Antiviral Res.* 2014;101:122-30. Epub 20131120. doi: 10.1016/j.antiviral.2013.11.006. PubMed PMID: 24269475; PubMed Central PMCID: PMC7113864.
58. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. *J Clin Invest.* 2010;120(1):214-22. Epub 20091221. doi: 10.1172/JCI40231. PubMed PMID: 20038800; PubMed Central PMCID: PMC2798692.
59. Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. *Hum Vaccin Immunother.* 2018;14(12):2820-41. Epub 20180906. doi: 10.1080/21645515.2018.1508624. PubMed PMID: 30096012; PubMed Central PMCID: PMC6343614.
60. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. *Haematologica.* 2020;105(6):1494-506. doi: 10.3324/haematol.2019.243543. PubMed PMID: 32482755; PubMed Central PMCID: PMC7271567.
61. Csizmar CM, Ansell SM. Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. *Int J Mol Sci.* 2021;22(7). Epub 20210324. doi: 10.3390/ijms22073302. PubMed PMID: 33804869; PubMed Central PMCID: PMC8038124.
62. Griggio V, Perutelli F, Salvetti C, Boccillato E, Boccadoro M, Vitale C, et al. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. *Front Immunol.* 2020;11:594556. Epub 20201118. doi: 10.3389/fimmu.2020.594556. PubMed PMID: 33312177; PubMed Central PMCID: PMC7708380.
63. Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, et al. SARS-CoV-2 evolution during treatment of chronic infection. *Nature.* 2021;592(7853):277-82. Epub 20210205. doi: 10.1038/s41586-021-03291-y. PubMed PMID: 33545711; PubMed Central PMCID: PMC7610568.


64. Weigang S, Fuchs J, Zimmer G, Schnepf D, Kern L, Beer J, et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. *Nat Commun.* 2021;12(1):6405. Epub 20211104. doi: 10.1038/s41467-021-26602-3. PubMed PMID: 34737266; PubMed Central PMCID: PMC8568958.
65. Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH, et al. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. *mSphere.* 2021;6(4):e0048021. Epub 20210825. doi: 10.1128/mSphere.00480-21. PubMed PMID: 34431691; PubMed Central PMCID: PMC8386433.
66. Borges V, Isidro J, Cunha M, Cochicho D, Martins L, Banha L, et al. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma. *mSphere.* 2021;6(4):e0024421. Epub 20210728. doi: 10.1128/mSphere.00244-21. PubMed PMID: 34319130; PubMed Central PMCID: PMC8386466.
67. Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell.* 2020;183(7):1901-12.e9. Epub 20201104. doi: 10.1016/j.cell.2020.10.049. PubMed PMID: 33248470; PubMed Central PMCID: PMC7640888.
68. Jensen B, Luebke N, Feldt T, Keitel V, Brandenburger T, Kindgen-Milles D, et al. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. *Lancet Reg Health Eur.* 2021;8:100164. Epub 20210714. doi: 10.1016/j.lanepe.2021.100164. PubMed PMID: 34278371; PubMed Central PMCID: PMC8278033.
69. Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, et al. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. *Cell.* 2021;184(10):2605-17.e18. Epub 20210316. doi: 10.1016/j.cell.2021.03.027. PubMed PMID: 33831372; PubMed Central PMCID: PMC7962548.
70. Salinas NR, Little DP. 2matrix: A utility for indel coding and phylogenetic matrix concatenation(1.). *Appl Plant Sci.* 2014;2(1). Epub 20140107. doi: 10.3732/apps.1300083. PubMed PMID: 25202595; PubMed Central PMCID: PMC4123383.
71. Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. *Nat Methods.* 2017;14(6):587-9. Epub 20170508. doi: 10.1038/nmeth.4285. PubMed PMID: 28481363; PubMed Central PMCID: PMC5453245.


Swabs




medRxiv preprint doi: <https://doi.org/10.1101/2022.03.04.22271540>; this version posted March 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).







medRxiv preprint doi: <https://doi.org/10.1101/2022.03.04.22271540>; this version posted March 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



1_NC_045512.2_SARS-CoV-2_isolate_Wuhan_Hu_1_complete_genome

(50) 2019_nCoV_EPI_ISL_2106192_day143
(95) 2019_nCoV_EPI_ISL_2106194_day164
2019_nCoV_MN90894756642_day_182
(61) 2019_nCoV_EPI_ISL_210619x_day171
2019_nCoV_EPI_ISL_2106193_day158
2019nCoV_EPI_ISL_2106201_day_136
2019_nCoV_EPI_ISL_2106197_day117
(76) 2019_nCoV_EPI_ISL_2106196_day93
(80) 2019_nCoV_EPI_ISL_2106200_day129
(100) 2019_nCoV_EPI_ISL_2106201_day123
2019_nCoV_EPI_ISL_2106199_day73

(93) hCoV_19_Austria_CeMM8274_2021
(67) hCoV_19_Austria_CeMM8300_2021
(96) hCoV_19_Austria_CeMM8302_2021
(100) hCoV_19_Austria_CeMM8295_2021
(83) hCoV_19_Austria_CeMM8299_2021
(84) hCoV_19_Greece_CP90891_2021_B_1_1_7
(82) hCoV_19_Netherlands_GR_UMCG_MMB_199_2021_B_1_1_7
(77) hCoV_19_Poland_NIPH_NIH_ECDC_4325_2021_B_1_1_7
(84) hCoV_19_Greece_90285_2021_B_1_1_7
(100) hCoV_19_Austria_CeMM8304_2021
(73) hCoV_19_Austria_LB_R00053_S037_2022EPI_ISL_90250532022_01_05
(66) hCoV_19_Austria_LB_R00053_S093_2022EPI_ISL_90250552022_01_05
(100) hCoV_19_Austria_LB_R00053_S051_2022EPI_ISL_90250522022_01_05
hCoV_19_Austria_LB_R00053_S057_2022EPI_ISL_90250542022_01_05
(85) hCoV_19_Belgium_MBLG51556_2021_P1_1
(100) hCoV_19_Italy_SIC_CQRC_21047942_2021_P1
(76) hCoV_19_Switzerland_ZH_32806695_2021_P1
(61) hCoV_19_Scotland_QEUA_157D552_2021_B_1_617
hCoV_19_Scotland_QEUA_157DA17_2021B_1_617
(100) hCoV_19_France_IDF_HMN_21052100591_2021_B_1_525
hCoV_19_France_IDF_HMN_21052120291_2021_B_1_525
(100) hCoV_19_Italy_EMR_136713_003_01_2021_B_1_525_1
hCoV_19_Italy_EMR_136713_004_01_2021_B_1_525_1
(76) hCoV_19_France_IDF_HMN_21052120324_2021_B_1_351
(77) hCoV_19_Poland_NIPH_NIH_ECDC_5112_2021B_1_351
(100) hCoV_19_Ireland_D_NVRL_89IRL84263_2021B_1_627_1_629
(84) hCoV_19_Norway_09851_2021B_1_627_1_629
hCoV_19_Wales_MILK_1576313_2021B_1_627_1_629

2.0E-4